Actelion Chooses GENEART as Exclusive Supplier for DNA Engineering &
Processing Services>
Actelion Chooses GENEART as Exclusive Supplier for DNA Engineering & Processing Services
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ - Framework agreement with Actelion Pharmaceuticals Ltd. signed- Actelion receives system solutions in the areas of geneoptimization, gene synthesis and plasmid preparation exclusively fromGENEART from now on- The service portfolio of GENEART accelerates product development inbiotechnology when compared to conventional methods of molecularbiology- DIN EN ISO 9001:2000 certification guarantees high qualitystandards for the development of pharmaceutical agentsRegensburg, July 7, 2009 - GENEART AG, global leader in GeneSynthesis and specialist in the field of Synthetic Biology, announcesthe signing of a framework agreement with the Swiss company ActelionPharmaceuticals Ltd. Within the scope of this agreement, Actelionwill receive system solutions for DNA engineering & processing (geneoptimization, gene synthesis and plasmid preparation) exclusivelyfrom GENEART from now on. Further contract terms were not disclosed.The contract does not restrict GENEART in supplying service solutionsfor other customers. The company, listed in the Swiss blue-chip indexSMI®, is active in research, development and commercialization ofinnovative biopharmaceutical therapies. The drugs developed andmarketed by Actelion include Tracleer® for instance - an endothelinreceptor antagonist for patients with pulmonary arterialhypertension."We are delighted that we have been able to convince anotherwell-known company, Actelion, of the advantages of our technology forthe development of biopharmaceutical therapeutics. Gene optimizationand gene synthesis offer many advantages over conventional methods inmolecular biology. For instance, genes can be tailored to therespective customer project by our GeneOptimizer® software withoutany restrictions and subsequently produced within a few days. Thisnot only shortens development times for biopharmaceuticals, but alsoincreases the yield and thus reduces production and project costs.The fully DIN EN ISO 9001:2000 certified processes of GENEART and theworld-wide highest production capacities additionally ensure reliableand quick processing of customer projects with observance of therequired quality standards for the development of pharmaceuticalagents", Prof. Dr. Ralf Wagner, CEO of GENEART AG, explains.For further inquiries, please contact:Dr. Karoline StürmerGENEART AGJosef-Engert-Str. 1193053 RegensburgGermanyPhone: +49-(0)941-942 76-417Fax: +49-(0)941-942 76-711ir(at)geneart.comwww.geneart.comFrank OstermairBetter Orange IR & HV AGHaidelweg 4881241 MunichGermanyPhone: +49-(0)89-8896906-10Fax: +49-(0)89-8896906-66info(at)better-orange.dewww.better-orange.deLegal Information:This document may contain estimates, prognoses and opinions aboutcompany plans and objectives, products or services, future results,opinions about these results or opinions leading up to these results.All these projections into the future are subject to risk,uncertainty and unforeseeable change outside the control of theGENEART Group. Many factors may lead to actual results, whichconsiderably deviate from the given projections for these results.About GENEART AG:In 2000, GENEART entered the gene synthesis market and has sincebecome the global market leader. Today, the company is one of theleading specialists in the Synthetic Biology field. Experts atGENEART provide key technologies for the development and productionof new therapeutics and vaccines. Customers also take advantage ofGENEART services to customize enzyme attributes, such as theattributes of enzymes used as detergent additives, and to constructbacteria, which produce complex biopolymers or break down polymers,such as synthetics, petroleum components, etc. Our production andservice spectrum spans a wide range, from the production of syntheticgenes according to DIN EN ISO 9001:2000, to the creation of genelibraries in the combinatorial biology, to the development andproduction of DNA-based biologically active substances. GENEART AG inRegensburg (Germany) and the subsidiaries GENEART Inc. in Toronto(Canada) and GENEART Inc. in San Francisco (USA) employ more than 190people. GENEART is listed on the German Stock Exchange.About Actelion Pharmaceuticals Ltd.:Actelion Pharmaceuticals Ltd. is a biopharmaceutical company with itscorporate headquarters in Allschwil/Basel, Switzerland. Actelion'sfirst drug Tracleer®, an orally available dual endothelin receptorantagonist, has been approved as a therapy for pulmonary arterialhypertension. Actelion markets Tracleer® through its own subsidiariesin key markets worldwide, including the United States (based in SouthSan Francisco), the European Union, Japan, Canada, Australia andSwitzerland. Actelion, founded in late 1997, is a leading player ininnovative science related to the endothelium - the single layer ofcells separating every blood vessel from the blood stream. Actelion'sover 2,000 employees focus on the discovery, development andmarketing of innovative drugs for significant unmet medical needs.Actelion shares are traded on the SIX Swiss Exchange (ticker symbol:ATLN) as part of the Swiss blue-chip index SMI® (Swiss Market Index).http://hugin.info/136633/R/1327235/312624.pdf --- End of Message ---Geneart AGJosef-Engert-Str.11 Regensburg GermanyWKN: A0JJ4L; ISIN: DE000A0JJ4L4; Listed: Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Berlin, Open Market in Frankfurter Wertpapierbörse, Freiverkehr in Börse Stuttgart;
" alt="REC ASA - Primary insiders transactions>">
" alt="Novartis extends tuberculosis drug donation to Tanzania>">
Datum: 07.07.2009 - 07:00 Uhr
Sprache: Deutsch
News-ID 3279
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 315 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion Chooses GENEART as Exclusive Supplier for DNA Engineering &
Processing Services>"
steht unter der journalistisch-redaktionellen Verantwortung von
Geneart AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
